Array Biopharma Inc.

Genentech, Inc.

Pfizer Corporation

Denali Therapeutics Inc.

Biogen Ma Inc.

Ventirx Pharmaceuticals, Inc.

Enliven, Inc.

Other

Hoffmann-La Roche Inc.

Astrazeneca Ab

Enliven Therapeutics, Inc.

F. Hoffmann-La Roche Ag

Sunesis Pharmaceuticals, Inc.

F. Hoffmann-La Roche Sa

Joseph P Lyssikatos

Eli M Wallace

Qian Zhao

Anthony A Estrada

Allison L Marlow

John E Robinson

Shelley Allen

T Brian Hurley

Zachary Kevin Sweeney

James F Blake

Ellen Ruth Laird

Javier De Vicente Fidalgo

Jianwen A Feng

George T Topalov

Hong Woon Yang

Jeongbeob Seo

Bin Ma

Brian T Hopkins

Alexandre Joseph Buckmelter

Michael Siu

Gnanasambandam Kumaravel

Thomas Daniel Aicher

Kevin Koch

Timothy Raymond Chan

Lewis J Gazzard

Huifen Chen

Alan G Olivero

Snahel Patel

Mark C Munson

Brian M Fox

Bingwei Vera Yang

Isaac E Marx

Brad Newhouse

Emily J Hanan

Paul Gibbons

Bing-Yan Zhu

Steven R Magnuson

Li Ren

Hazel Joan Dyke

Matthew Lynn Peterson

Richard Pastor

Lei Zhang

Lihong Sun

Erik James Hicken

Stephen T Schlachter

Laurence Edward Burgess

Kevin X Chen

Christopher Hurley

Jermaine Thomas

Nicholas C Kallan

Tracy J Jenkins

Brian Stuart Lucas

Robert Hershberg

Simon Charles Goodacre

Karen Williams

Vishal Verma

Calum MacLeod

Jun Liang

Wendy Lee

Mark Edward Zak

Matthew Volgraf

Kirk D Robarge

Zheng Jane Li

Emanuela Gancia

Rohan V Mendonca

Robert A Volkmann

Janusz Jozef Kulagowski

Yimin Qian

Sung-Sau So

Stephen Colin Price

Peter Scott Dragovich

George A Doherty

Kevin Guckian

Zhonghua Pei

Michael Luzzio

Bryan K Chan

Anantha R Sudhakar

Wayne E Barth

James P Rizzi

Robert Andrew Heald

Shawn David Erickson

Steven Huy Do

Aleksandr Kolesnikov

Daniel Fred Ortwine

John Charles Kath

Peter Michael Wovkulich

Timothy Heffron

Frederick Cohen

Sharada Shenvi Labadie

Charles Baker-Glenn

Allen John Lovey

Po-Wai Yuen

Robert D Groneberg

Shaoqing Chen

Kyungjin Kim

Scott J Hecker

Srinivasan Babu

Christine E Brotherton-Pleiss

Charles Todd Eary

Lan Wang

The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.

Compounds, compositions and methods

The present disclosure relates to compounds and compositions for inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).

5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases

The present invention relates to deuterated and optionally detectably labeled compounds of formula (I) and formula (V): and salts thereof, wherein R, R, A, and X-Xhave any of the values defined in the specification. Also included are pharmaceutical compositions comprising such compounds and salts, and methods of using such compounds and salts as imaging agents.

Imaging methods using deuterated compounds

This invention provides compounds of Formula I wherein B, G, A, E, R, R, R, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.

N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases

Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

Inhibiting agents for bruton's tyrosine kinase

The present disclosure relates generally to compounds of formula (I) or a pharmaceutically acceptable salt, prodrug, deuterated analog, tautomer, stereoisomer, or mixture of stereoisomers thereof and their use as LRRK2 inhibitors.

Substituted pyrimidines as LRKK2 inhibitors

The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.

Compounds, compositions, and methods

The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.

Fused tetracyclic quinazoline derivatives as inhibitors of ErbB2

5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

Biaryl inhibitors of Bruton's tyrosine kinase

Deuterated compounds

Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production. Formula (I) The compounds are IRAK-4 inhibitors useful for treating an inflammatory disease, an autoimmune disease, cancer, a cardiovascular disease, a disease of the central nervous system, a disease of the skin, an ophthalmic disease and condition, and a bone disease. 

IRAK4 inhibiting agents

Inhibiting agents for Bruton's tyrosine kinase

Growing community of inventors

Piedmont, CA, United States of America

Joseph P Lyssikatos